Induction of HLA-A2-restricted CTL responses by a tubular structure carrying human melanoma epitopes

被引:9
作者
Ghosh, MK
Li, CL
Fayolle, C
Dadaglio, G
Murphy, A
Lemonnier, FA
Roy, P
Leclerc, C
机构
[1] Inst Pasteur, Unite Biol Regulat Immunitaires, F-75724 Paris 15, France
[2] Univ Alabama Birmingham, Sch Med, Dept Med, Div Geog Med, Birmingham, AL 35924 USA
[3] Inst Pasteur, Unite Immunol Cellulaire Antivirale, F-75724 Paris 15, France
[4] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England
关键词
melanoma; HHD mice; CTL responses; chimeric BTV NS1 tubules;
D O I
10.1016/S0264-410X(02)00185-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epitope-based vaccination strategies designed to induce strong tumor-specific CD8(+) T cell responses are being widely considered for cancer immunotherapy. Here, two recombinant tubular structures, NS1-Mela 1 and NS1-Mela 2, carrying, respectively two HLA-A2 epitopes derived from human melanoma antigens were constructed and their capability to induce CTL responses in vivo were studied in HLA-A2 transgenic mice. Strong CTL responses specific for GnT-V/NA 17-A and gp100 (154-162) epitopes were generated in HLA-A2 transgenic mice immunized by the construct NS1-Mela 1 carrying these two epitopes. The second construct NS1-Mela 2 carrying both Tyrosinase (369-377 Da) and Melan-A/Mart-1 (27-35) epitopes induced a weak Tyrosinase-specific CTL response in mice but failed to induce specific CTL responses against the Melan-A/Mart-1 (27-35) epitope in the tested mice. Thus, recombinant tubular structures containing multiple tumoral epitopes may lead to new strategies for the induction of strong tumor-specific CTL responses in cancer patients. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2463 / 2473
页数:11
相关论文
共 44 条
[31]   In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity [J].
Sedlik, C ;
Dadaglio, G ;
Saron, MF ;
Deriaud, E ;
Rojas, M ;
Casal, SI ;
Leclerc, C .
JOURNAL OF VIROLOGY, 2000, 74 (13) :5769-5775
[32]   An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins [J].
Skipper, JCA ;
Hendrickson, RC ;
Gulden, PH ;
Brichard, V ;
VanPel, A ;
Chen, Y ;
Shabanowitz, J ;
Wolfel, T ;
Slingluff, CL ;
Boon, T ;
Hunt, DF ;
Engelhard, VH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (02) :527-534
[33]  
SLINGLUFF CL, 1993, J IMMUNOL, V150, P2955
[34]   MINIMAL EPITOPES EXPRESSED IN A RECOMBINANT POLYEPITOPE PROTEIN ARE PROCESSED AND PRESENTED TO CD8(+) CYTOTOXIC T-CELLS - IMPLICATIONS FOR VACCINE DESIGN [J].
THOMSON, SA ;
KHANNA, R ;
GARDNER, J ;
BURROWS, SR ;
COUPAR, B ;
MOSS, DJ ;
SUHRBIER, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (13) :5845-5849
[35]  
Thomson SA, 1998, J IMMUNOL, V160, P1717
[36]   Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction [J].
Toes, REM ;
Offringa, R ;
Blom, RJJ ;
Melief, CJM ;
Kast, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7855-7860
[37]  
URAKAWA T, 1988, J VIROL, V68, P2169
[38]   Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue [J].
Valmori, D ;
Lévy, F ;
Miconnet, I ;
Zajac, P ;
Spagnoli, GC ;
Rimoldi, D ;
Liénard, D ;
Cerundolo, V ;
Cerottini, JC ;
Romero, P .
JOURNAL OF IMMUNOLOGY, 2000, 164 (02) :1125-1131
[39]  
VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x
[40]  
WANG M, 1995, J IMMUNOL, V154, P4685